PAX6 and neoplasm: Here, our stage-specific analysis of TCGA mutation data for non-ultramutated EECs showed that KLF3 and PAX6 are SMGs in late-stage (III/IV) but not early-stage (I/II) disease, raising the possibility that KLF3 and PAX6 mutations undergo positive selection during tumor progression.